Bios Partners
17
17M
11
1.89
6
0.35
2
- Areas of investment
Summary
The fund was located in North America if to be more exact in United States. The main office of represented VC is situated in the Fort Worth.
For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Health Care, Clinical Trials. Besides, a startup needs to be aged 2-3 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Lantern Pharma, Incysus Therapeutics, 410 Medical The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager.
This organization was formed by Aaron Fletcher. Besides them, we counted 5 critical employees of this fund in our database.
Considering the real fund results, this VC is 50 percentage points more often commits exit comparing to other organizations. The common things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually. The important activity for fund was in 2019.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Bios Partners, startups are often financed by UT Horizon Fund, Technium Partners, Tech Coast Angels. The meaningful sponsors for the fund in investment in the same round are DEFTA Partners, KdT Ventures, Kairos Ventures. In the next rounds fund is usually obtained by WakeMed Health & Hospitals, Venture Capital Multiplier Fund, U.S. Department of Defense.
Investments analytics
Analytics
- Total investments
- 17
- Lead investments
- 6
- Exits
- 2
- Rounds per year
- 1.89
- Follow on index
- 0.35
- Investments by industry
- Biotechnology (15)
- Health Care (10)
- Therapeutics (9)
- Pharmaceutical (5)
- Medical (5) Show 8 more
- Investments by region
-
- United States (17)
- Peak activity year
- 2019
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 11
- Avg. valuation at time of investment
- 1M
- Group Appearance index
- 0.82
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| ONL Therapeutics | 08 Mar 2023 | Biotechnology, Pharmaceutical, Therapeutics | Late Stage Venture | 15M | United States, Ann Arbor, Michigan |
| Trefoil Therapeutics | 16 Jul 2019 | Biotechnology, Health Care, Therapeutics | Early Stage Venture | 28M | United States, California, San Diego |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.